[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_103":104,"_105":57},"item-original",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":25,"_29":30,"_31":32,"_33":34,"_35":36,"_37":38,"_39":-5,"_38":40,"_41":-5,"_42":-5,"_43":-5,"_44":45,"_46":47,"_48":-5,"_49":50,"_51":52,"_53":54,"_55":36,"_56":57,"_58":-5,"_59":60,"_61":62,"_63":36,"_64":57,"_65":66},"id","cn1ixxwyd504hs80i75158dfz","revision",1,"title","🚨 #ESMO26 Presidential 2 | SAFFRON Ph3","originalTitle","summary","reason","source",{"_11":97,"_77":98,"_99":100,"_101":36,"_102":-5},"links",{"_94":95,"_66":96},"publishedAt","2026-10-25T14:24:57.000Z","discoveredAt","2026-10-25T14:37:27.527Z","timelineAt","category","opinion","tags",[],"score",70,"selected",false,"channel","x","story",{"_86":47,"_87":47,"_88":-5,"_89":-5,"_90":91,"_92":93},"insight","digest","conferenceAbstracts","readingMode","full","author","OncUpdates","language","body",{"_81":-5,"_66":82,"_83":84,"_85":57},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_75":76,"_77":78,"_79":-5,"_80":-5},"engagement",{"_67":68,"_69":14,"_70":71,"_72":14,"_73":74},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",2,"likes","replies",0,"reposts","views",25,"slug","esmo-2026","name","ESMO 2026","topic","reading","zh","

🚨 #ESMO26 Presidential 2 | SAFFRON Ph3

Osimertinib + savolitinib vs platinum–pemetrexed in EGFRm MET-OE and/or -AMP advanced #NSCLC post-osimertinib
✅ mPFS: 7.6 vs 5.4 mo
✅ mOS:17.8 vs 12.9 mo
✅ Median DoR: 9.7 vs 5.7 mo
⚠️Grade ≥3 TRAEs:40% vs 52%

#LCSM #EGFR #OncTwitter

","zhKind","translation","complete","authorName","handle","avatarUrl","quoted","thread",[],"media",[],"aihot","/items/cn1ixxwyd504hs80i75158dfz","https://x.com/OncUpdates/status/2114362581473173973","esmo26-floor","ESMO 2026 现场信号","kind","x_search","firstParty","iconUrl","changelogVersion","2026-10-24T20:30","enEditionEnabled"]